Physician Request Form for Opioid Containing Products

Fax to Pharmacy Services at 1-855-446-7894 or call 1-866-935-8874 to speak to a representative.

Form must be complete for processing.

Patient name:	Patient ID:	
Patient address:	Date of Birth:	
City:State:Zip:		
Prescriber name:	NPI:	
Prescriber address:	Phone:	
City: State: Zip:	Fax:	
Contact name:		
Prescriber specialty:		
Requested drug name, strength and dosage form:		
Directions:	Duration of therapy:	
Diagnosis:		
Is the patient in hospice? □Yes □No		
Is the patient a resident of a long-term care facility? ☐Yes ☐No		
Does the patient have cancer? ☐Yes ☐No		
FOR INITIAL REQUESTS		
Prescriber attests to the following:		
 For long-acting products, the diagnosis is chronic pain and red □ N/A 	quires daily, around-the-clock opioid medication. \square Yes \square No	
 The patient has tried and failed non-pharmacologic treatment and two non-opioid containing pain medications (ex. acetaminophen, NSAIDs, select antidepressants, anticonvulsants). □Yes * □No *If yes provide drug names: 		
If the request is for a dose or day supply greater than the limit/restriction, provide documentation of medical necessity for the requested dose or submit along with this form.		
 Is the patient taking a concurrent benzodiazepine? □Yes* □ * If yes, the prescriber attests to discussing the risks of using opioids Provide documentation as to why concurrent use is necessary and 	and benzodiazepines concurrently with the patient: \square Yes \square No	
	pleted at baseline and will be completed every 6 months. If illicit I the heightened risk of overdose will be explained to the patient	



, , , , , , , , , , , , , , , , , , ,	the Millinesota Frescription Monitoring	, , ,		
• The prescriber attests to disprescribed.	cussing with the patient the level of risk for o	pioid abuse/overdose with the dose/duration		
Does the patient have a high-risk condition as stated in the CDC guidelines (ex. sleep apnea or other causes of sleep-disordered breathing, patients with renal or hepatic insufficiency, older adults, pregnant women, patients with depression of other mental health conditions, and patients with alcohol or other substance use disorders)? —Yes* No *If yes, the prescriber attests to discussing heightened risks of opioid use and has educated the patient on naloxone use and has considered prescribing naloxone. —Yes No				
-	The prescriber attests that the member has entered into a pain management agreement. \Box Yes \Box No* *If no, is the member currently residing in a facility? \Box Yes \Box No			
-	rmulary opioid, the patient must meet the abo oid medications (if available). Please list medi	ove criteria and have a trial and failure or intolerance cations:		
scriber Signature:	Print Name:	Date:		
Provide documentation of patie this form.	ent's pain improvement (i.e. improvement in s	everity level of pain) below or submit along with		
• • • •	nt benzodiazepine? □Yes* □No cussing the risks of using opioids and benzodiazepin why concurrent use is necessary and outline a plan	· ·		
*If yes, the prescriber attests to dis Provide documentation as to	cussing the risks of using opioids and benzodiazeping why concurrent use is necessary and outline a plan opposed oppos	· · · · · · · · · · · · · · · · · · ·		
*If yes, the prescriber attests to dis Provide documentation as to	cussing the risks of using opioids and benzodiazeping why concurrent use is necessary and outline a plant opy of at least one urine drug screen (UDS) sinults):	for tapering if appropriate:		



	**If opioids are not found on the urine drug screen, provide documentation as to why the patient needs to co therapy or submit along with this form.		
•	The prescriber attests to checking history. □Yes □No	the Minnesota Prescription Monitoring Prog	ram (PMP) for member
Pre	scriber Signature:	Print Name:	Date: